Patent intelligence · US
US 11938134
Metalloenzyme inhibitor compounds
Metalloenzyme inhibitor compounds
Patent details — US 11938134
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 26, 2024
- Expiration
- Mar 21, 2044
- Applicant
- Eikonizo Therapeutics, Inc.
- Claims
- 1
- CPC classes
- A61K, A61K31/506
Quick answer
US 11938134 (Metalloenzyme inhibitor compounds) is held by Eikonizo Therapeutics, Inc.. Status: granted. Granted Mar 26, 2024. Expires Mar 21, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Eikonizo Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 1
- CPC classes
- A61K, A61K31/506
More from Eikonizo Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11938134?
US 11938134 (Metalloenzyme inhibitor compounds) is held by Eikonizo Therapeutics, Inc.. Status: granted. Granted Mar 26, 2024. Expires Mar 21, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11938134?
Eikonizo Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 11938134 expire?
Our index shows an expiration date of Mar 21, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.